Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 1003-1009

  Mariele, DESSÌ ^a   Piras, Alessandra ^a   Madeddu, Clelia ^a   Cadeddu, Christian ^a   Deidda, Martino ^a   Massa, Elena ^a   Antoni, Giorgia ^a   Giovanni, Mantovani ^a   Mercuro, Giuseppe ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cytokines; Epirubicin induced cardiotoxicity; Oxidative stress; Renin angiotensin system; Telmisartan

Indexed keywords

EPIRUBICIN; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPOTENSION; INFLAMMATION; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALIVARY GLAND CANCER; SYSTOLE; TISSUE DOPPLER IMAGING;

EID: 79960205893     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.305     Document Type: Article

References (26)

1. Escobar E, Rodriguez-Reyna TS, Arrieta O and Sotelo J: Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2: 385-399, 2004.
2. Thompson KL, Rosenzweig BA, Zhang J, et al: Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 66: 303-314, 2010.
3. Funao K, Matsuyama M, Kawahito Y, et al: Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 20: 295-300, 2008.
4. Paulides M and Wojnowski L: [Chemotherapeutics-induced heart failure]. Med Klin 102: 574-578, 2007 (In German).
5. Meldrum DR, Cleveland JC Jr, Cain BS, Meng X and Harken AH: Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg 65: 439-443, 1998.
6. Kupatt C, Habazettl H, Goedecke A, et al: Tumor necrosis factor-alpha contributes to ischemia- and reperfusion-induced endothelial activation in isolated hearts. Circ Res 84: 392-400, 1999.
7. Mercuro G, Cadeddu C, Piras A, et al: Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12: 1124-1133, 2007.
8. Mantovani G, Madeddu C, Cadeddu C, et al: Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 13: 1296-1305, 2008.
9. Toko H, Oka T, Zou Y, et al: Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 25: 597-603, 2002.
10. Soga M, Kamal FA, Watanabe K, et al: Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol 110: 378-385, 2006.
11. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
12. Iqbal M, Dubey K, Anwer T, Ashish A and Pillai KK: Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 60: 382-390, 2008.
13. Ishiguro H, Ishiguro Y, Kubota Y and Uemura H: Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 67: 924-932, 2007.
14. Cadeddu C, Piras A, Mantovani G, et al: Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160: e481-e487, 2010.
15. Wenzel P, Schulz E, Oelze M, et al: AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 45: 619-626, 2008.
16. Stephen RL, Gustafsson MC, Jarvis M, et al: Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 64: 3162-3170, 2004.
17. Jensen BV, Skovsgaard T and Nielsen SL: Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13: 699-709, 2002.
18. Jalowy A, Schulz R and Heusch G: AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol 93 (Suppl 2): 85-91, 1998.
19. Ferreira AL, Matsubara LS and Matsubara BB: Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 6: 278-281, 2008.
20. Cianchetti S, del Fiorentino A, Colognato R, di Stefano R, Franzoni F and Pedrinelli R: Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 198: 22-28, 2008.
21. Yamagishi S and Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 64: 476-478, 2005.
22. Tuck ML: Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. Curr Hypertens Rep 7: 240-243, 2005.
23. Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229, 2004.
24. Conklin KA: Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 4: 110-130, 2005.
25. Kaur K, Sharma AK, Dhingra S and Singal PK: Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol 41: 1023-1030, 2006.
26. Sipahi I, Debanne SM, Rowland DY, Simon DI and Fang JC: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11: 627-636, 2010.